Aarti Drugs Ltd - Stock Valuation and Financial Performance

BSE: 524348 | NSE: AARTIDRUGS | Pharmaceuticals & Drugs | Small Cap

Aarti Drugs Ltd Share Price

530.45 -5.35 -1.00%
as on 23-Feb'24 16:59

DeciZen - make an informed investing decision on Aarti Drugs

Overall Rating
Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Semi Strong

Aarti Drugs stock performance -

mw4me loader
P/E Ratio (CD):
27.06
Market Cap:
4,876.7 Cr.
52-wk low:
310.8
52-wk high:
645

Is Aarti Drugs Ltd an attractive stock to invest in?

1. Is Aarti Drugs Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Aarti Drugs Ltd is a average quality company.

2. Is Aarti Drugs Ltd undervalued or overvalued?

The key valuation ratios of Aarti Drugs Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Aarti Drugs Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Aarti Drugs Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Aarti Drugs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Aarti Drugs Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'11Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 9.3%18%12.8%12.6%11.6%11.5%15.8%25.9%15.7%11.4%-
Value Creation
Index
-0.30.3-0.1-0.1-0.2-0.20.10.90.1-0.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 5011,0971,1401,1951,2441,5611,8062,1552,4892,7162,651
Sales YoY Gr.-118.9%3.9%4.9%4.1%25.5%15.7%19.3%15.5%9.1%-
Adj EPS 2.587.18.48.79.214.829.822.11819.6
YoY Gr.-224.4%-11.2%18.8%3.7%5.8%60.6%101.1%-25.8%-18.9%-
BVPS (₹) 16.831.836.941.948.357.67098111.9128.8135.6
Adj Net
Profit
23.977.368.780.382.387.1138278205166180
Cash Flow from Ops. 20.610513317569.814325115570.4134-
Debt/CF from Ops. 134.33.62.77.83.51.52.27.74.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 20.7%16.9%14.6%9.1%
Adj EPS 24.7%15.5%6.6%-18.9%
BVPS25.4%21.7%22.5%15.1%
Share Price 34.5% 29.1% -5.8% 45.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'11Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
15.432.820.721.219.217.423.135.52114.914.8
Op. Profit
Mgn %
13.815.715.815.916.213.514.720.413.411.412.2
Net Profit
Mgn %
4.7766.76.65.67.712.98.26.16.8
Debt to
Equity
1.61.51.41.21.20.90.60.40.50.5-
Working Cap
Days
15612116216219117817016518019592
Cash Conv.
Cycle
90618176949189829910735

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 14.57%

Return on Equity has declined versus last 3 years average to 14.80%

Net Profit has been subdued in last 3 years 6.57%

Sales growth is not so good in last 4 quarters at -0.56%

Latest Financials - Aarti Drugs Ltd.

Standalone Consolidated
TTM EPS (₹) 17.3 19.6
TTM Sales (₹ Cr.) 2,404 2,651
BVPS (₹.) 124.8 135.6
Reserves (₹ Cr.) 1,055 1,154
P/BV 4.25 3.91
PE 30.69 27.06
From the Market
52 Week Low / High (₹) 310.80 / 645.00
All Time Low / High (₹) 0.57 / 1025.00
Market Cap (₹ Cr.) 4,877
Equity (₹ Cr.) 91.9
Face Value (₹) 10
Industry PE 48.6

Management X-Ray of Aarti Drugs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Aarti Drugs

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Balance Sheet

(All Figures are in Crores.)

Profit And Loss

(All Figures in Cr. Adjusted EPS in Rs.)

Cash Flow

(All Figures are in Crores.)

Aarti Drugs Ltd Stock News

Aarti Drugs Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Aarti Drugs on 23-Feb-2024 16:59 is ₹530.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Feb-2024 16:59 the market cap of Aarti Drugs stood at ₹4,876.7.
The latest P/E ratio of Aarti Drugs as of 23-Feb-2024 16:59 is 30.69.
The latest P/B ratio of Aarti Drugs as of 23-Feb-2024 16:59 is 4.25.
The 52-week high of Aarti Drugs is ₹645.0 and the 52-week low is ₹310.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Aarti Drugs is ₹2,404 ( Cr.) .

About Aarti Drugs Ltd

Aarti Drugs Ltd. was established in the year 1984 and forms part of $900 Million Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations.

Over the years, the Company has been able to carve a niche for itself and is looking forward to expand the volumes. With the government initiative to encourage private health insurance schemes, consumer spending on medicines is expected to increase, which will spur growth in the generic sector in the domestic market.

The manufacturing-units of Aarti Drugs Ltd. are GMP certified. The Company is also in the process of acquiring an ISO 9002 compliance for all its units and one of the units has already been approved.

The Company aims at becoming the first choice of this expanding market through better products, ensuring quality and timely delivery.

Business area of the company

The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science Private Limited.

Products under APIs includes Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.

Awards and accolades

  • 1991-1992: Outstanding Performance in Export from Chemexcil
  • 2001: Best Vendor from Organization of Pharmaceutical Product
  • 2005: Customer Responsiveness from Avaya Global Connect
  • 2013: Business Partner of the year from Abbott
  • 2014: Appreciation as business partner from Abbott
  • 2014: Certificate of Recognition - Star Export House from Government of India (Ministry of Commerce and Industry)
  • 2015: Business Partner of the year from Abbott
  • 2006: Customer Responsiveness from Avaya Global Connect
  • 2016: Business Partner of the year from Abbott
  • 2016: Outstanding Performance in Export from Pharmexcil
  • 2017: Business Partner of the year from Abbott
  • 2017: Outstanding Performance Latin American Export from Pharmexcil
  • 2018: Business Partner of the year from Abbott

Milestones

  • 1984: Incorporation
  • 1993: Listed On BSE Limited
  • 1996: Amalgamation of Rupal Chemical Industries Limited, Rashesh Chemicals & Pharmaceuticals Limited, Manjarati Chemicals Private Limited, Manjarati Plastisizer Private Limited, Effective Chemicals Private Limited, Star Aluminium Industries Limited and Avez Wire
  • 1998: Turnover of Rs 100 crore
  • 2003: Listed On National Stock Exchange of India Limited
  • 2008: Approval of USFDA Plant
  • 2011: Turnover of Rs 500 crore
  • 2014: Turnover of Rs 1000 crore 100% holdings in Pinnacle Life Science Pvt.  Ltd.
  • 2015: Aarti Drugs Limited -PBT More than Rs 100 crore
  • 2017: Rs 100 crore Turnover Pinnacle Life Science Pvt. Ltd. Pinnacle Life Science (Sikkim) Plant ready for operations
  • 2019: Turnover of Rs 1500 crore
  • 2020: Crossed Rs 2000 crore consolidated turnover and Rs 200 crore formulation turnover
  • 2020: Crossed PAT amounted Rs 200 crore
  • 2022: Consolidated revenue Rs 2500 crore
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.